Srk-015
SMA
Scholar Rock, Inc.Phase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the SMA cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Riluzole Assistance Publique - Hôpitaux de Paris | Phase 2/3 | B |
Pyridostigmine UMC Utrecht | Phase 2 | B |
Same molecule, other indications
Srk-015 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →